{"doi":"10.7554/elife.89423.3.sa3","title":"Author response: Nanobody repertoire generated against the spike protein of ancestral SARS-CoV-2 remains efficacious against the rapidly evolving virus","abstract":null,"journal":null,"year":2024,"id":680405,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":562460,"name":"Fred D Mast","orcid":null,"position":1,"is_corresponding":false},{"id":1777702,"name":"Peter C Fridy","orcid":null,"position":2,"is_corresponding":false},{"id":565786,"name":"Jean Paul Olivier","orcid":"0000-0002-2197-271X","position":3,"is_corresponding":false},{"id":649827,"name":"Tanmoy Sanyal","orcid":"0000-0002-6009-9431","position":4,"is_corresponding":false},{"id":91650,"name":"Andrej Sali","orcid":null,"position":5,"is_corresponding":false},{"id":905624,"name":"Brian T Chait","orcid":null,"position":6,"is_corresponding":false},{"id":1326067,"name":"Michael P Rout","orcid":"0000-0002-9353-9456","position":7,"is_corresponding":false},{"id":562463,"name":"John D Aitchison","orcid":null,"position":8,"is_corresponding":false},{"id":1777696,"name":"Natalia E Ketaren","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Author response: Nanobody repertoire generated against the spike protein of ancestral SARS-CoV-2 remains efficacious against the rapidly evolving virus","abstract":"To date, all major modes of monoclonal antibody therapy targeting SARS-CoV-2 have lost significant efficacy against the latest circulating variants.As SARS-CoV-2 omicron sublineages account for over 90% of COVID-19 infections, evasion of immune responses generated by vaccination or exposure to previous variants poses a significant challenge.A compelling new therapeutic strategy against SARS-CoV-2 is that of single-domain antibodies, termed nanobodies, which address certain limitations of monoclonal antibodies.Here, we demonstrate that our high-affinity nanobody repertoire, generated against wild-type SARS-CoV-2 spike protein (Mast et al., 2021), remains effective against variants of concern, including omicron BA.4/BA.5; a subset is predicted to counter resistance in emerging XBB and BQ.1.1 sublineages.Furthermore, we reveal the synergistic potential of nanobody cocktails in neutralizing emerging variants.Our study highlights the power of nanobody technology as a versatile therapeutic and diagnostic tool to combat rapidly evolving infectious diseases such as SARS-CoV-2. eLife assessmentThis study presents important insights on the impact of SARS-CoV-2 variants on the binding and neutralization of a small library of nanobodies.The authors should be applauded for their comprehensive in vitro and in silico analyses of nanobody targeting of SARS-CoV-2 variants.The evidence supporting the claims of the authors is now convincing.This work will be of great interest to researchers in the fields of antibody/nanobody engineering and SARS-CoV-2 therapeutics.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"21097893","pmcid":null,"openalex_id":"https://openalex.org/W4396706089","authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://elifesciences.org/download/aHR0cHM6Ly9jZG4uZWxpZmVzY2llbmNlcy5vcmcvYXJ0aWNsZXMvODk0MjMvZWxpZmUtODk0MjMtdjEucGRmP2Nhbm9uaWNhbFVyaT1odHRwczovL2VsaWZlc2NpZW5jZXMub3JnL2FydGljbGVzLzg5NDIz/elife-89423-v1.pdf?_hash=VTWXZFc%2FCQGDBVuKCJ6NvuG7Q1MM4uVPppUzG7NXu4Q%3D","host_type":""},{"url":"https://elifesciences.org/download/aHR0cHM6Ly9jZG4uZWxpZmVzY2llbmNlcy5vcmcvYXJ0aWNsZXMvODk0MjMvZWxpZmUtODk0MjMtdjEucGRmP2Nhbm9uaWNhbFVyaT1odHRwczovL2VsaWZlc2NpZW5jZXMub3JnL2FydGljbGVzLzg5NDIz/elife-89423-v1.pdf?_hash=VTWXZFc%2FCQGDBVuKCJ6NvuG7Q1MM4uVPppUzG7NXu4Q%3D","host_type":""},{"url":"http://dx.doi.org/10.7554/elife.89423.3.sa3","host_type":""}],"fields_of_study":["SARS-CoV-2 and COVID-19 Research","Biosensors and Analytical Detection","Advanced Biosensing Techniques and Applications"],"mesh_terms":[],"keywords":["Spike Protein","Spike (software development)","Repertoire","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","Sars virus","Coronavirus disease 2019 (COVID-19)","Virology","Biology","2019-20 coronavirus outbreak","Virus","Evolutionary biology","Computational biology","Computer science","Medicine","Outbreak","Physics","Infectious disease (medical specialty)"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-17T15:03:43.011596Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}